HALOZYME THERAPEUTICS, INC. Annual Operating Lease, Payments in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Halozyme Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from 2018 to 2023.
  • Halozyme Therapeutics, Inc. Operating Lease, Payments for the quarter ending September 30, 2024 was $1.6M, unchanged year-over-year.
  • Halozyme Therapeutics, Inc. Operating Lease, Payments for the twelve months ending September 30, 2024 was $6.8M, a 4.62% increase year-over-year.
  • Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $6.7M, a 59.5% increase from 2022.
  • Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $4.2M, a 55.6% increase from 2021.
  • Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2021 was $2.7M, a 15.6% decline from 2020.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $6.7M +$2.5M +59.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-20
2022 $4.2M +$1.5M +55.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-20
2021 $2.7M -$500K -15.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-20
2020 $3.2M +$100K +3.23% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $3.1M +$700K +29.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-22
2018 $2.4M Jan 1, 2018 Dec 31, 2018 10-K 2020-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.